Scientific article
Open access

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1

ContributorsNAMSAL ANRS 12313 Study Group
CollaboratorsCalmy, Alexandraorcid
Published inNew England Journal of Medicine, vol. 381, no. 9, p. 816-826
Publication date2019

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.

  • Adult
  • Benzoxazines/administration & dosage/adverse effects
  • Drug Therapy, Combination
  • Female
  • HIV Infections/drug therapy
  • HIV Integrase Inhibitors/adverse effects/therapeutic use
  • HIV-1/genetics/isolation & purification
  • Heterocyclic Compounds, 3-Ring/administration & dosage/adverse effects
  • Humans
  • Lamivudine/administration & dosage
  • Male
  • Obesity/chemically induced
  • Pregnancy
  • RNA, Viral/blood
  • Tenofovir/administration & dosage
  • Viral Load/drug effects
  • Weight Gain/drug effects
Research group
  • Autre - ANRS 12313
Citation (ISO format)
NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. In: New England Journal of Medicine, 2019, vol. 381, n° 9, p. 816–826. doi: 10.1056/NEJMoa1904340
Main files (1)
Article (Published version)
ISSN of the journal0028-4793

Technical informations

Creation10/23/2020 3:10:00 PM
First validation10/23/2020 3:10:00 PM
Update time03/15/2023 11:37:57 PM
Status update03/15/2023 11:37:56 PM
Last indexation05/05/2024 5:41:24 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack